Tiny Blood-Based Genetic Clue Could Transform Detection of Childhood Heart Defects

Congenital heart disease, the most common birth defect worldwide, arises when the embryonic heart fails to form correctly, and its steadily rising prevalence has pushed researchers to search for earlier, more precise ways to identify children at risk. A new study published in BMC Pediatrics by Xiaoran Liu, Yinhuan Li, and Wenhong Ding now adds a striking piece to that puzzle, linking a single circulating microRNA and two genetic variants to the disease in children. The work, conducted across the Pediatric Cardiac Center at Beijing Anzhen Hospital of Capital Medical University and the Ultrasound Department of Hengshui Maternal and Child Health Hospital, suggests that a simple blood-based marker combined with a genetic test could one day sharpen the diagnosis of pediatric congenital heart disease long before symptoms demand invasive workups.

The research team enrolled 158 children diagnosed with congenital heart disease and 150 age-matched healthy controls, a sample size large enough to detect meaningful differences in both gene expression and genetic susceptibility. The study received ethics approval from the Medical Ethics Committee of Hengshui Maternal and Child Health Hospital, and written informed consent was obtained from all participants and the guardians of minor participants in accordance with the Declaration of Helsinki. The central question was deceptively simple: does the level of microRNA-122 in the blood differ between children with structural heart defects and healthy children, and can inherited variants at the microRNA-122 gene locus explain part of that difference?

MicroRNAs are short, non-coding RNA molecules, roughly 18 to 25 nucleotides long, that fine-tune gene expression after transcription by binding target messenger RNAs and blocking their translation or triggering their degradation. MicroRNA-122 is particularly famous in molecular medicine as a liver-specific microRNA, but it also circulates in serum in a remarkably stable form, protected from degradation by RNA-degrading enzymes. That stability makes circulating microRNAs attractive as liquid biopsy biomarkers: unlike traditional protein markers, they resist freezing, thawing, and long storage, and quantitative polymerase chain reaction can detect them with exquisite sensitivity. In the developing heart, microRNAs orchestrate the tightly choreographed gene programs that guide cardiac morphogenesis, so perturbations in their levels or in the regulatory regions that control their production could plausibly contribute to structural malformations.

To measure expression, the investigators collected serum specimens and quantified microRNA-122 using reverse transcription quantitative polymerase chain reaction, the gold-standard technique for nucleic acid quantification. The method converts RNA to complementary DNA and then amplifies a specific target sequence, with fluorescent TaqMan probes allowing precise measurement of how much starting material was present. For the genetic side of the study, the team genotyped two single nucleotide polymorphisms at the microRNA-122 locus, rs9966765 and rs17669, again using TaqMan assays. Single nucleotide polymorphisms are positions in the genome where a single DNA letter varies between individuals, and when such variants fall in or near regulatory regions of a microRNA gene, they can alter how much of that microRNA is produced, creating a direct genetic-epigenetic connection between inherited DNA sequence and gene regulation.

The results were unambiguous on the expression front. Children with congenital heart disease exhibited significantly lower serum microRNA-122 levels than the healthy controls. More importantly for clinical translation, receiver operating characteristic curve analysis showed that microRNA-122 maintained favorable discriminative performance, meaning the biomarker could reliably separate affected children from unaffected ones. Receiver operating characteristic analysis plots sensitivity against one minus specificity across all possible cutoff values, and the area under the resulting curve provides a single number summarizing diagnostic accuracy, where 1.0 represents perfect discrimination and 0.5 represents a coin flip. The authors further stress-tested their diagnostic model using two complementary validation strategies: ten-fold cross-validation, in which the data are repeatedly split into training and testing subsets to evaluate performance on unseen cases, and one thousand bootstrap replicates for internal validation, a resampling technique that adjusts the apparent area under the curve for statistical optimism. Together, these analyses indicate that the biomarker’s performance is not an artifact of overfitting the original dataset.

The genetic findings were equally compelling, and here the two polymorphisms diverged sharply. Carrying the C allele at rs9966765, or being homozygous for it with the CC genotype, significantly raised the risk of congenital heart disease, and carriers of this risk genotype also displayed lower microRNA-122 expression. This is the kind of coherent biological story that genetic epidemiologists look for: a variant that not only correlates statistically with disease but also plausibly explains the disease mechanism by suppressing the very regulatory molecule implicated in the condition. In contrast, rs17669 showed no association with either congenital heart disease risk or microRNA-122 levels, appearing essentially neutral. The divergence between the two loci strengthens the overall conclusion, because it demonstrates that the signal is specific to rs9966765 rather than a general property of the region or a technical artifact of the genotyping platform.

To account for potential confounding factors, the team fitted multivariate logistic regression models, a statistical framework that estimates the independent contribution of each variable to disease risk while holding other measured factors constant. In these models, rs9966765 remained significantly associated with congenital heart disease and exerted the strongest genetic effect among the variables examined. Logistic regression converts the outcome into the logarithm of the odds of disease and estimates coefficients that can be translated into odds ratios, allowing researchers to quantify how much a given allele or genotype multiplies risk. The supplementary material adds an intriguing clinical dimension: stratified linear-fit regression analyses examined the relationship between left-ventricular end-diastolic diameter, a standard echocardiographic measure of heart chamber size, and microRNA-122 expression according to rs9966765 genotype, comparing the GG genotype group with the combined CG and CC risk-carrier subgroup. This suggests the authors probed whether the genetic variant modifies the anatomical correlates of the biomarker, hinting at genotype-specific patterns in cardiac structure.

The significance of this work lies in how it bridges two layers of biology that are usually studied separately. Genetic association studies identify inherited DNA variants that shift disease risk, while expression studies measure the dynamic molecular output of the genome. When a risk allele at a specific locus is shown to be accompanied by reduced expression of the gene at that same locus, and when that gene’s product is itself a validated disease biomarker, the chain of evidence becomes unusually tight. In this case, the C allele at rs9966765 appears to dampen microRNA-122 production, and reduced microRNA-122 in turn marks or potentially contributes to abnormal cardiac development. The authors describe this as establishing a credible genetic-epigenetic link in congenital heart disease pathogenesis, a framing that positions microRNA-122 not merely as a passive biomarker but as a candidate participant in the disease process itself.

For clinicians, the immediate implication is a potential new diagnostic indicator for congenital heart disease in children. Current diagnosis relies heavily on echocardiography, an imaging technique that requires specialized equipment and expertise and may miss subtle defects, particularly in resource-limited settings. A serum biomarker measurable by standard quantitative polymerase chain reaction could complement echocardiographic screening, flag children who warrant closer imaging follow-up, and potentially support earlier detection in newborns. Because circulating microRNAs are stable and the assay is technically straightforward, the approach could in principle be adapted to large-scale screening programs, though the authors are careful to note that their findings provide a foundation for future validation rather than a finished clinical tool.

That caution is well placed, and the authors themselves outline the path forward: validation in larger cohorts stratified by congenital heart disease subtype. Congenital heart disease is not one disease but a family of dozens of distinct malformations, from septal defects to complex outflow tract abnormalities, each with its own developmental origins. A biomarker and genetic variant that associate broadly with the disease category may behave differently within specific subtypes, and larger, subtype-stratified studies will be needed to determine whether microRNA-122 and rs9966765 carry particular weight in particular malformations. Functional studies will also be needed to establish whether the rs9966765 variant directly regulates microRNA-122 transcription and whether reduced microRNA-122 causally contributes to defective heart development or simply tracks alongside it. Still, the convergence of expression data, genetic association, rigorous diagnostic validation, and multivariate risk modeling in a single pediatric cohort makes this study a notable advance, and it offers a glimpse of a future in which a few drops of blood and a snippet of DNA sequence help identify which children carry hidden vulnerabilities in the very architecture of their hearts.

Subject of Research: MicroRNA-122 expression and rs9966765/rs17669 variants as biomarkers and risk factors in pediatric congenital heart disease

Article Title: Potential clinical value of miR-122 expression and genetic locus variants in pediatric congenital heart disease

Article References: Liu, X., Li, Y., & Ding, W. (2026). Potential clinical value of miR-122 expression and genetic locus variants in pediatric congenital heart disease. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07581-0

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07581-0

Keywords: congenital heart disease, microRNA-122, rs9966765, rs17669, single nucleotide polymorphism, biomarker, pediatrics, genetic susceptibility, RT-qPCR, ROC curve, cardiac development, liquid biopsy